LexisNexis® Legal Newsroom
Lawsuits Follow Diabetes Drug Actos' Link To Cancer Risk

TRENTON, N.J. - (AP) The maker of the world's best-selling diabetes drug is facing hundreds of lawsuits and likely a big sales drop as suspicion grows that taking the pill for more than a year raises the risk of bladder cancer. In June, Takeda Pharmaceuticals Co. Ltd. halted sales of Actos. . . ...

California State Jury Awards $6.5 Million In 1st Actos Bladder Cancer Case To Go To Trial

LOS ANGELES - (Mealey's) A California state court jury on April 26 awarded $6.5 million in the first Actos bladder cancer case to go to trial, according to the parties ( Jack Cooper v. Takeda Pharmaceuticals America Inc. , CGC-12-518535, Calif. Super., Los Angeles Co.). The parties said the jury...

Maryland Jury Awards $1.7 Million In 2nd Actos Bladder Cancer Case

BALTIMORE — (Mealey’s) A Maryland state court jury on Sept. 26 awarded $1.76 million in the second Actos bladder cancer case to go to trial ( An v. Takeda Pharmaceuticals America, Inc. , No. 24-C12003565, Md. Cir., Baltimore City). ( Verdict sheet available. Document #28-131003-013V ....

Jury Awards $9B In 1st MDL Actos Bladder Cancer Trial Against Takeda, Eli Lilly

LAFAYETTE, La. — (Mealey’s) The first federal court Actos bladder cancer trial ended April 7 in a $9 billion verdict against co-defendants Takeda Pharmaceuticals USA Inc. and Eli Lilly & Co. Inc., according to Takeda ( In Re: Actos [Pioglitazone] Products Liability Litigation , MDL Docket...

Illinois Jury Finds For Takeda In Actos Bladder Cancer Trial

CHICAGO — (Mealey’s) An Illinois state court jury on May 15 returned a defense verdict in an Actos bladder cancer death case after four weeks of testimony ( In Re: Actos Litigation , No. 11 L 010011, Diane Whitlatch, et al. v. Takeda Pharmaceuticals America, Inc., et al. , No. 12 L 6087,...

Nevada State Court Jury Returns Defense Verdict In 2-Plaintiff Actos Cancer Trial

LAS VEGAS — (Mealey's) A Nevada state court jury on May 22 returned a unanimous defense verdict in a 32-day, two-plaintiff Actos bladder cancer trial, but two plaintiff attorneys say they will seek a new trial because they believe their objections to what the judge labeled “misconduct”...

Pennsylvania State Court Jury Awards Plaintiff $2 Million In Actos Bladder Cancer Case

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Oct. 3 awarded an Actos bladder cancer patient $2.05 million in economic and noneconomic damages but declined to award punitive damages ( Frances Wisniewski v. Takeda Pharmaceuticals America Inc., et al. , No. 120702272, Pa. Comm...

No New Trial In Actos MDL Bellwether Case, But Punitives Are Cut From $9 Billion To $36 Million

LAFAYETTE, La. — (Mealey’s) Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co. will not get a new trial in the first Actos bladder cancer multidistrict litigation bellwether case, but a Louisiana federal judge on Oct. 27 reduced the $9 billion punitive damages verdict to $36.87 million...

W.Va. Jury Finds Spoliation Of Evidence, Awards $155,000 Against Actos Manufacturer Takeda

MARTINSBURG, W.Va. — (Mealey’s) A West Virginia state court jury on Nov. 17 found that Actos is not unsafe and that manufacturer Takeda Pharmaceutical Co. Ltd. was not negligent in the case of a man who developed bladder cancer while taking the diabetes drug, but the panel did find spoliation...

Takeda To Pay Up To $2.4 Billion To Settle About 9,000 Actos Bladder Cancer Claims

LAFAYETTE, La. — (Mealey’s) Takeda Pharmaceutical Co. Ltd. will pay up to $2.4 billion to settle the “vast majority” of Actos bladder cancer lawsuits in the United States, the company, plaintiff attorneys and the multidistrict litigation court said April 28 ( In Re: Actos [Pioglitazone...

California Appeals Court Reinstates $6.5 Million Actos Verdict; Expert Back In

LOS ANGELES — (Mealey’s) A California appeals court panel on July 16 reinstated a $6.5 million Actos bladder cancer verdict, finding that the trial court erred in excluding the plaintiffs’ causation expert in a post-verdict ruling ( Nancy Cooper, et al. v. Takeda Pharmaceuticals America...